Fulcrum Therapeutics Inc

FULC

NASDAQ. Currency in USD

6.04 +0.69 ( +12.90% )

Real time prices: December 19

Market Cap.
314.39M
Beta (5Y monthly)
1.95
Price/Earnings
-
EPS (TTM)
-2.55
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.16M
1y Target Est.
21.89
Day's Range
5.42
-
6.15
52 Week's Range
3.21
-
24.79

Historical Summary

Performance
EPS growth
Share Buybacks

About Fulcrum Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.fulcrumtx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
32.68M
Employees
104
Address
26 Landsdowne Street, Cambridge, MA, United States, 02139
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest news

Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying

Although US stocks closed lower on Friday, there were a few notable insider trades. When...
By Benzinga - 6 weeks ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage...
By GlobeNewswire Inc. - 7 weeks ago

Can Fulcrum Therapeutics, Inc. (FULC) Climb 232% to Reach the Level Wall Street Analysts Expect?
Can Fulcrum Therapeutics, Inc. (FULC) Climb 232% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Fulcrum Therapeutics, Inc. (FULC) points to a 232.1%...
By Zacks Investment Research - 8 weeks ago

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage...
By GlobeNewswire Inc. - 8 weeks ago

Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 232% as Wall Street Analysts Expect?
Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 232% as Wall Street Analysts Expect?

The consensus price target hints at a 232.3% upside potential for Fulcrum Therapeutics, Inc. (FULC)....
By Zacks Investment Research - 10 weeks ago

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage...
By GlobeNewswire Inc. - 11 weeks ago

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates
Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 19.35% and 45.86%, respectively, for...
By Zacks Investment Research - 11 weeks ago

Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

― Selected 12mg as the dose for next cohort in the Phase 1b trial of...
By GlobeNewswire Inc. - 11 weeks ago